Radiopharm Theranostics Limited (RAD) Price & Analysis

Compare

18 Followers

RAD Stock Chart & Stats

Day’s Range― - ―

52-Week RangeAU$0.02 - AU$0.04

Previous CloseN/A

Volume5.13M

Average Volume (3M)3.00M

Market Cap

AU$56.76M

Enterprise ValueAU$6.42M

Total Cash (Recent Filing)AU$36.44M

Total Debt (Recent Filing)AU$0.00

Price to Earnings (P/E)―

Beta0.62

Next Earnings

Sep 25, 2025

EPS Estimate

-0.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.01

Shares Outstanding2,364,949,500

10 Day Avg. Volume5,365,781

30 Day Avg. Volume2,996,519

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

AU$0.05

Price Target Upside150.00% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Market ExposureThe launch of American Depository Shares, with plans for a secondary listing on Nasdaq, positions Radiopharm for broader market exposure.

Partnership OpportunitiesRadiopharm's portfolio of imaging and therapeutic radiopharmaceutical agents provides the company with opportunities for medium- to long-term growth and potential non-dilutive capital via partnerships.

Therapeutic PipelineRadiopharm Theranostics has focused its therapeutic pipeline on biologically validated targets that have seen limited or no use in radiopharmaceuticals, which is designed to de-risk development and limit competition.

Bears Say

Capital RaiseThe AUD 70M capital raise resulted in higher dilution than previously estimated due to associated lower prices.

Radiopharm Theranostics Limited News

Radiopharm reports FY25 closing cash balance $29.12M

Net cash outflows from operating activities for the year totaled $36.67 million. Direct Research and Development expenditure and...

16d ago

RADX

Radiopharm receives IND approval from US FDA to initiate study of RV-01

Radiopharm (RADX) Theranostics announced that the U.S. Food and Drug Administration, FDA, has provided clearance of the Company’s...

17d ago

RADX

Radiopharm appoints Sartor to Scientific Advisory Board

Radiopharm (RADX) Theranostics announces the appointment of DrOliver Sartor, MD to the Company’s Scientific Advisory Board, SAB. Published...

23d ago

RADX

Radiopharm initiated with a Buy at Brookline

Brookline analyst Kemp Dolliver initiated coverage of Radiopharm (RADX) with a Buy rating and $18 price target The...

24d ago

RADX

Radiopharm Theranostics: Promising Pipeline and Strategic Advancements Drive Buy Rating

Analyst Michael Okunewitch of Maxim Group maintained a Buy rating on Radiopharm Theranostics Limited Sponsored ADR, retaining the...

15d ago

RADX

Radiopharm Theranostics Limited: Promising Clinical Developments and Strategic Growth Potential Drive Buy Rating

Radiopharm Theranostics Limited Sponsored ADR, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst...

16d ago

RADX

Radiopharm Theranostics Advances Clinical Programs with Key Milestones

The latest update is out from Radiopharm Theranostics Limited ( ($AU:RAD) ). Radiopharm Theranostics announced its fiscal year...

16d ago

RAD

Radiopharm Theranostics Gains FDA Approval for Phase I Study of Innovative Cancer Treatment

An update from Radiopharm Theranostics Limited ( ($AU:RAD) ) is now available. Radiopharm Theranostics has received FDA approval...

18d ago

RAD

Radiopharm Theranostics Appoints Dr. Oliver Sartor to Scientific Advisory Board

The latest update is out from Radiopharm Theranostics Limited ( ($AU:RAD) ). Radiopharm Theranostics has appointed Dr. Oliver...

24d ago

RAD

Radiopharm Theranostics Secures A$4.5 Million R&D Tax Incentive

Radiopharm Theranostics Limited ( ($AU:RAD) ) has provided an update. Radiopharm Theranostics Limited has received a research and...

30d ago

RAD

Radiopharm, Cyclotek signs clinical supply agreement for Tb-KLK3-mAb

Radiopharm (RADX) Theranostics announced the signing of a supply agreement with Cyclotek to radiolabel RAD 402 with Terbium-161...

2M ago

RADX

Radiopharm Theranostics Advances Prostate Cancer Trial with Cyclotek Partnership

An announcement from Radiopharm Theranostics Limited ( ($AU:RAD) ) is now available. Radiopharm Theranostics has announced a clinical...

2M ago

RAD

Radiopharm Theranostics Limited – American Depositary Shares trading resumes

10:51 EDT Radiopharm (RADX) Theranostics Limited – American Depositary Shares trading resumes Published first on TheFly – the...

2M ago

RADX

Radiopharm Theranostics Announces Change in Substantial Holder Interests

The latest update is out from Radiopharm Theranostics Limited ( ($AU:RAD) ). Radiopharm Theranostics Limited has announced a...

2M ago

RAD

RAD FAQ

What was Radiopharm Theranostics Limited’s price range in the past 12 months?

Radiopharm Theranostics Limited lowest share price was AU$0.02 and its highest was AU$0.04 in the past 12 months.

What is Radiopharm Theranostics Limited’s market cap?

Radiopharm Theranostics Limited’s market cap is AU$56.76M.

When is Radiopharm Theranostics Limited’s upcoming earnings report date?

Radiopharm Theranostics Limited’s upcoming earnings report date is Sep 25, 2025 which is in 42 days.

How were Radiopharm Theranostics Limited’s earnings last quarter?

Radiopharm Theranostics Limited released its earnings results on Feb 28, 2025. The company reported -AU$0.01 earnings per share for the quarter, the consensus estimate of -AU$0.01 by AU$0.

Is Radiopharm Theranostics Limited overvalued?

According to Wall Street analysts Radiopharm Theranostics Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Radiopharm Theranostics Limited pay dividends?

Radiopharm Theranostics Limited does not currently pay dividends.

What is Radiopharm Theranostics Limited’s EPS estimate?

Radiopharm Theranostics Limited’s EPS estimate is -0.01.

How many shares outstanding does Radiopharm Theranostics Limited have?

Radiopharm Theranostics Limited has 2,364,949,500 shares outstanding.

What happened to Radiopharm Theranostics Limited’s price movement after its last earnings report?

Radiopharm Theranostics Limited reported an EPS of -AU$0.01 in its last earnings report, expectations of -AU$0.01. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Radiopharm Theranostics Limited?

Currently, no hedge funds are holding shares in AU:RAD

Radiopharm Theranostics Limited Stock Smart Score

Neutral

Fundamentals

Return on Equity

-108.26%

Trailing 12-Months

Asset Growth

46.07%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Radiopharm Theranostics Limited

Radiopharm Theranostics Limited develops radiopharmaceutical products for diagnostic and therapeutic uses. The company was incorporated in 2021 and is based in Carlton, Australia.

Radiopharm Theranostics Limited (RAD) Earnings & Revenues

Historic Earnings Reports

RAD Stock 12 Month Forecast

Average Price Target

AU$0.05

▲(150.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"AU$0","1":"AU$1","-1":"-AU$1","-0.5":"-AU$0.5","0.5":"AU$0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.05,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$0.05</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.05,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$0.05</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.05,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$0.05</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2023","6":"Jan<br/>2024","9":"Oct<br/>2024","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.03,0.031538461538461536,0.03307692307692307,0.03461538461538462,0.036153846153846154,0.03769230769230769,0.03923076923076923,0.040769230769230766,0.04230769230769231,0.04384615384615385,0.045384615384615384,0.04692307692307693,0.04846153846153846,{"y":0.05,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.03,0.031538461538461536,0.03307692307692307,0.03461538461538462,0.036153846153846154,0.03769230769230769,0.03923076923076923,0.040769230769230766,0.04230769230769231,0.04384615384615385,0.045384615384615384,0.04692307692307693,0.04846153846153846,{"y":0.05,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.03,0.031538461538461536,0.03307692307692307,0.03461538461538462,0.036153846153846154,0.03769230769230769,0.03923076923076923,0.040769230769230766,0.04230769230769231,0.04384615384615385,0.045384615384615384,0.04692307692307693,0.04846153846153846,{"y":0.05,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.1,"date":1672531200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.12,"date":1675209600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.12,"date":1677628800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.12,"date":1677628800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.15,"date":1680307200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.13,"date":1685577600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.07,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.03,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.04,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.03,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.02,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.02,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.03,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >